The clinical efficacy of therapeutic antibodies against oncology targets is largely dependent upon their ability to recruit the host immune system. The predominant mechanism of action (MoA) in this context is Antibody-Dependent Cellular Cytotoxicity (ADCC). The binding affinity between the antibody’s Fc region and the Fc gamma RIIIA (CD16a) receptor on natural killer (NK) cells is the premier critical quality attribute (CQA) governing ADCC potency.

It is now scientifically established that the presence of core fucose on the N-glycan at position Asn-297 causes steric hindrance, reducing affinity for Fc gamma RIIIA. By eliminating this core fucose, we can achieve up to a 100-fold increase in binding affinity, translating directly into potent anti-tumor activity even in tumor environments with low antigen expression or in patients with low-affinity CD16a polymorphisms.

The Pronewbio Platform Solution for Fucose-Free Production

Achieving stable, reproducible, and complete afucosylation during large-scale manufacturing remains a challenge in conventional CHO systems. Many standard expression platforms result in heterogeneous glycosylation profiles that necessitate extensive downstream purification or post-translational enzymatic modifications.

Pronewbio Biotech Ltd. has developed a proprietary, robust afucosylated antibody expression platform centered on precisely engineered host cell lines. Rather than relying on non-specific metabolic inhibitors like 2-fluorofucose, which can alter cell viability and overall product quality, we utilize advanced genomic tools to create definitive knockout (KO) lineages.

Our platform primarily deploys specialized mammalian systems:

1. Engineered FUT8 Knockout (KO) CHO Systems: This represents the gold standard. We have permanently silenced the $\alpha$-1,6-fucosyltransferase (FUT8) gene. Without the FUT8 enzyme, the transfer of fucose from GDP-$\beta$-L-fucose to the core GlcNAc residue is biochemically impossible, guaranteeing 100% afucosylation without affecting antibody titer or stability.
2. Specialized Alternative Expression Systems: For specific projects requiring unique glycan architecture, we offer engineered non-mammalian host systems (such as customized yeast or filamentous fungi platforms) designed to produce homogeneous, simple N-glycans that are inherently fucose-free and optimized for super-physiological receptor binding.

Service Workflow: From Sequence to Characterized Candidate

Our platform integrates seamlessly into a comprehensive production workflow optimized for the demanding requirements of therapeutic scale-up.

• Construct Design & Sequence Optimization: Codon optimization tailored for high expression in engineered host systems and incorporation of proprietary high-expression vectors.
• Stable Pool or Clonal Cell Line Generation: Utilization of rigorous selection protocols to identify high-producing, robust FUT8 KO clones with stable phenotypes.
• Process Optimization & Scale-Up: Evaluation of fed-batch fermentation parameters in 5L-200L+ stirred-tank bioreactors to maximize antibody titer while maintaining desired glycan CQAs.
• Downstream Purification: Standardized Protein A/G capture followed by multi-step polishing chromatography to achieve >95% purity and ultra-low endotoxin levels.

Analytical Release Criteria and Deliverables

We understand that the utility of an afucosylated antibody depends entirely on rigorous analytical verification. Every batch produced by our platform undergoes exhaustive glycan analysis and functional validation:

Deliverable Quality Assessment (Included in QC Report):

• N-Glycan Profiling: Mandatory verification of afucosylation via High-Performance Liquid Chromatography (HPLC) coupled with Fluorescence Detection (HILIC-FLD) or high-resolution Mass Spectrometry (MS). We guarantee <1% residual fucosylation.
• Fc gamma RIIIA (CD16a) Binding Affinity: Quantitative assessment using Surface Plasmon Resonance (SPR) to confirm the super-physiological binding compared to wild-type control antibodies.
• Standard Biophysical Characterization: Complete analysis including SDS-PAGE (purity), SEC-HPLC (aggregation), and LAL (endotoxin quantification).

By deploying the Pronewbio Afucosylated Antibody Expression Platform, researchers can confidently move from discovery to preclinical validation with a molecule optimized for maximum therapeutic impact.